Print Page

給 醫 護 專 業 人 員 的 信
 
Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals (Letter to Healthcare Professionals) (English only)
 
 
 
附件:
  1. Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals (English only)  
Related Information:
Canada: BEOVU (brolucizumab): Risk of intraocular inflammation, retinal vasculit... 上載於 2022-02-04
The United Kingdom: Brolucizumab (Beovu▼): risk of intraocular inflammation and ... 上載於 2022-01-19
 
back